Silence Therapeutics’ chief executive officer Ali Mortazavi has been appointed non-executive chairman of ultromics – an artificial intelligence-focused medical imaging firm.
Mortazavi has 17 years’ experience in UK companies, particularly in the biotechnology investment field and joined London-based biotech Silence Therapeutics in 2012 leading its refinancing business and driving business.
He said: “I am truly excited to be joining the board of ultromics. Artificial intelligence will increasingly begin to play a bigger role in medicine as well as other sectors. Ultromics plans to use the combination of man plus machine rather than man vs Machine in medical imaging.”
Ultromics – formed in May 2017 – is backed by Oxford Sciences Innovation and the technology has been applied to echocardiograms to improve the diagnostic accuracy of coronary artery disease from 80% to greater than 95%.